The role of antiplatelet therapy in the secondary prevention of coronary artery disease

Current Opinion in Cardiology

Volumn 25, Issue 4, 2010, Pages 321-328

  Behan, Miles W ^a   Chew, Derek P ^a   Aylward, Philip E ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

antiplatelet therapy; aspirin; clopidogrel; coronary disease; prasugrel; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BLEEDING; BONE MARROW SUPPRESSION; BRADYCARDIA; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DYSPNEA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; LOADING DRUG DOSE; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RASH; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS; URIC ACID BLOOD LEVEL;

ADENOSINE; ASPIRIN; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; SECONDARY PREVENTION; THIOPHENES; THROMBOXANE A2; TICLOPIDINE;

EID: 77953812881     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328338f7b5     Document Type: Review

References (45)

1. Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J 2004; 80:155-164.
2. Feit F, Voeltz MD, Attubato MJ, et al. Predictors and impact of major haemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial. Am J Cardiol 2007; 100:1364-1369.
3. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114:774-782.
4. Patrano C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287-1294.
5. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324:71-78.
6. ISIS-2 (Second International study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 2:349-360.
7. Antithrombotic Trialists Collaboration (ATT). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849- 1860.
8. Mehta SR, Bassard JP, Chrolavicius S, et al. Design and rationale of CURRENTOASIS 7: a randomized 2x2 factorial trial evaluating optimal dose strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 2008; 156:1080-1088.
9. Mehta SR, on behalf of the Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions (CURRENT OASIS-7) investigators. CURRENT-STEMI PCI: double dose versus standard dose clopidogrel in ACS patients undergoing PCI for STEMI. European Society of Cardiology; 24 September 2009. http://www.theheart. org/article995967.do. [Accessed 11 March 2010]
10. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/ AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51:210-247.
11. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/ non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1-e57.
12. King SB 3rd, Smith SC Jr, Hirshfield JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51:172-209.
13. Gengo FM, Rainka M, Gengo MF, et al. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischaemic events. J Clin Pharmacol 2008; 48:335-343.
14. Wurtz M, Grove EL, Kristensen SD, Hvas A-M. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 2009; 96:368-371.
15. Kam PC, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists) pharmacology and clinical developments. Anaesthesia 2003; 58:28-35.
16. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic- drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671.
17. Yeh SP, Hsueh EJ,WuH, Wang YC. Ticlopidine-associated aplastic anaemia. A case report and review of literature. Ann Haematol 1998; 76:87-90.
18. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12:1255-1259.
19. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
20. Yusuf S, Zhoa F, Mehta SR, et al. Clopidogrel in unstable angina to prevent recurrent events trial. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
21. Sabatine MS, Cannon CP, Gibson M, et al.; CLARITY-TIMI 28 Investigators. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY): Thrombolysis in Myocardial Infarction (TIMI) 28. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST segment elevation. N Engl J Med 2005; 352:1179-1189.
22. Chen ZM, Jiang LX, Chen YP, et al., COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: a randomized placebo controlled trial. Lancet 2005; 366:1607-1621.
23. Bhatt DL, Fox KA, Hacke W, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717.
24. Bhatt DL, Flather MD, Hacke W, et al., on behalf of the CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49:1982-1988.
25. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354-362.
26. Husted S. Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Fundament Clin Pharmacol 2009; 23:1-9.
27. Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet effect of clopidogrel associated with aspirin. J Am Coll Cardiol 2008; 51:256-260.
28. Ho PM, Thomas M, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301:937-944.
29. O'Donoghue ML, Braunwald E, Antman EA, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials. Lancet 2009; 374:989-997.
30. Bhatt DL, on behalf of the COGENT Investigators. Clopidogrel and the Optimization of Gastrointestinal Events (COGENT) trial. http://www.theheart. org/article1007145.do. [Accessed 11 March 2010]
31. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29:21-30.
32. Wiviott SD, Trenk D, Frelinger AL, et al., PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation- Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
33. Wivott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015. (Pubitemid 350106708)
34. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115:2344-2351.
35. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to assess Improvement in Therapeutic Outcomes by optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118:1626-1636.
36. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST elevation myocardial infarction (TRITON-TIMI 38): double blind, randomised controlled trial. Lancet 2009; 373:723-731.
37. US Food and Drug Administration. Cardiovascular and Renal drug Advisory Committee briefing document on prasugrel for ACS. http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. [Accessed 16 January 2010]
38. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50:1852-1856.
39. Gurbel PA, Bliden KP, Butler K, et al. Randomized double blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patents with stable coronary disease: the ONSET/OFFSET study. Circulation 2009; 120:2577-2585.
40. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
41. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006; 24:116-147.
42. Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009; 103 (Suppl): 40A-51A.
43. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomized, double blind, placebo controlled phase II study. Lancet 2009; 373:919-928.
44. Berger JS, Roe MT, Gibson CM, et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid Reversal of Platelet Thrombosis with Intravenous Elinogrel before PCI to Optimize Reperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009; 158:998.e1-1004.e1.
45. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention. Circulation 2010; 121: 71-79.